Abstract 1241: Enhancing NK cell therapy for head and neck cancer within the solid tumor microenvironment using a B7H3-targeting tri-specific killer engager (TriKE)
Melissa Khaw(University of Minnesota), Jeffrey S. Miller(Science Museum of Minnesota), Nicholas A. Zorko(University of Minnesota Medical Center), Carly Selleck(University of Minnesota), Naomi Fujioka(University of Minnesota), Martin Felices(University of Minnesota), Peter Hinderlie(University of Minnesota), Zachary Davis(University of Minnesota), Laura E. Bendzick(University of Minnesota), John E. Wagner(Kings County Hospital Center), James Lim(XCell Science (United States)), Ann Lu(XCell Science (United States)), Madison Shackelford(University of Minnesota System), Margaret L. MacMillan(University of Minnesota Medical Center)
Cited by 0
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
|Journal of Clinical Oncology|2008|202
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|180